UNLABELLED: In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the results by evaluating other poxvirus vectors and combinations with DNA and protein vaccines. Earlier clinical trials (EuroVacc trials 01 to 03) evaluated the immunogenicity of HIV-1 clade C GagPolNef and gp120 antigens delivered via the poxviral vector NYVAC. These showed that a vaccination regimen including DNA-C priming prior to a NYVAC-C boost considerably enhanced vaccine-elicited immune responses compared to those with NYVAC-C alone. Moreover, responses were improved by using three as opposed to two DNA-C primes. In the present study, we assessed in nonhuman primates whether such vaccin...
A therapeutic vaccine for individuals infected with HIV-1 and treated with antiretroviral therapy (A...
Producing a prophylactic vaccine for human immunodeficiency virus (HIV) has proven to be a challenge...
AbstractA therapeutic vaccine for individuals infected with HIV-1 and treated with antiretroviral th...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
The use of heterologous immunization regimens and improved vector systems has led to increases in im...
The use of heterologous immunization regimens and improved vector systems has led to increases in im...
An effective human immunodeficiency virus type 1 (HIV-1) vaccine must induce protective antibody res...
UNLABELLED: We compared the HIV-1-specific cellular and humoral immune responses elicited in rhesus ...
Background: In order to improve the immunogenicity of currently available non-replicating pox virus ...
As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccin...
The Thai trial (RV144) indicates that a prime-boost vaccine combination that induces both T-cell and...
Induction of HIV-specific T-cell responses by vaccines may facilitate efficient control of HIV. Plas...
T cell immunity plays a critical role in controlling HIV-1 viremia, and encoding a limited set of HI...
A preventive human immunodeficiency virus type 1 (HIV-1) vaccine is an essential part of the strateg...
A therapeutic vaccine for individuals infected with HIV-1 and treated with antiretroviral therapy (A...
Producing a prophylactic vaccine for human immunodeficiency virus (HIV) has proven to be a challenge...
AbstractA therapeutic vaccine for individuals infected with HIV-1 and treated with antiretroviral th...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
The use of heterologous immunization regimens and improved vector systems has led to increases in im...
The use of heterologous immunization regimens and improved vector systems has led to increases in im...
An effective human immunodeficiency virus type 1 (HIV-1) vaccine must induce protective antibody res...
UNLABELLED: We compared the HIV-1-specific cellular and humoral immune responses elicited in rhesus ...
Background: In order to improve the immunogenicity of currently available non-replicating pox virus ...
As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccin...
The Thai trial (RV144) indicates that a prime-boost vaccine combination that induces both T-cell and...
Induction of HIV-specific T-cell responses by vaccines may facilitate efficient control of HIV. Plas...
T cell immunity plays a critical role in controlling HIV-1 viremia, and encoding a limited set of HI...
A preventive human immunodeficiency virus type 1 (HIV-1) vaccine is an essential part of the strateg...
A therapeutic vaccine for individuals infected with HIV-1 and treated with antiretroviral therapy (A...
Producing a prophylactic vaccine for human immunodeficiency virus (HIV) has proven to be a challenge...
AbstractA therapeutic vaccine for individuals infected with HIV-1 and treated with antiretroviral th...